176 related articles for article (PubMed ID: 34051208)
1. Synthesis and antileukemic activity of an ursolic acid derivative: A potential co-drug in combination with imatinib.
da Silva EF; de Vargas AS; Willig JB; de Oliveira CB; Zimmer AR; Pilger DA; Buffon A; Gnoatto SCB
Chem Biol Interact; 2021 Aug; 344():109535. PubMed ID: 34051208
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia.
Waechter F; da Silva GNS; Willig JB; de Oliveira CB; Vieira BD; Trivella DBB; Zimmer AR; Buffon A; Pilger DA; Gnoatto SCB
Anticancer Agents Med Chem; 2017; 17(13):1777-1785. PubMed ID: 28403779
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
5. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
6. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
7. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
[TBL] [Abstract][Full Text] [Related]
8. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of Novel Ursolic acid Derivatives as Potential Anticancer Prodrugs.
Yang X; Li Y; Jiang W; Ou M; Chen Y; Xu Y; Wu Q; Zheng Q; Wu F; Wang L; Zou W; Zhang YJ; Shao J
Chem Biol Drug Des; 2015 Dec; 86(6):1397-404. PubMed ID: 26077799
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib.
Eskandari S; Yazdanparast R
J Cell Biochem; 2019 Jun; 120(6):10128-10136. PubMed ID: 30548309
[TBL] [Abstract][Full Text] [Related]
11. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.
Dar BA; Lone AM; Shah WA; Qurishi MA
Eur J Med Chem; 2016 Mar; 111():26-32. PubMed ID: 26854375
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
16. [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
Liu YY; You LS; Qian WB; Tong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):473-8. PubMed ID: 23086637
[TBL] [Abstract][Full Text] [Related]
17. A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb.
Zhang B; Zhang T; Zhang TY; Wang N; He S; Wu B; Jin HX
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708403
[TBL] [Abstract][Full Text] [Related]
18. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Evaluation of Anticancer Activities of Novel C-28 Guanidine-Functionalized Triterpene Acid Derivatives.
Spivak A; Khalitova R; Nedopekina D; Dzhemileva L; Yunusbaeva M; Odinokov V; D'yakonov V; Dzhemilev U
Molecules; 2018 Nov; 23(11):. PubMed ID: 30453551
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor potential of new arylidene ursolic acid derivatives via caspase-8 activation.
He B; Zhu Z; Chen F; Zhang R; Chen W; Zhang T; Wang T; Lei J
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000448. PubMed ID: 33646592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
